Saturday, January 10, 2009
pehel.com
Home Latest News Pakistan World Science / Technology Sports Entertainment Health Business


FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes
Source: Medical News Today E-Mail this News Story to a friend E-Mail this Story
Category: Health
Publication Date: Sat, 11 Oct 2008 00:00:00 PDT
News URL: http://www.medicalnewstoday.com/articles/125148.php
FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 DiabetesTakeda Pharmaceutical Company Limited ("Takeda") announced that Takeda Global Research and Development Center, Inc., a wholly owned United States (U.S.) subsidiary, received notification that the U.S.
Click here for full Story
http://www.medicalnewstoday.com/articles/125148.php
Bookmark this news story online:
Add FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to BlinkListAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to DeliciousAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to DiggAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to FarkAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to FurlAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to BlogarithmAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to MeneameAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to My Yahoo!Add FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to ReddItAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to ShadowsAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to SimpyAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to SpurlAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to Sync2ItAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to MagnoliaAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to NewsVineAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to Ask Jeeves
Add FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to Raw SugarAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to DiigoAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to NetVouzAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to Stumble UponAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to SegnaloAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to Google BookmarksAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to Microsoft LiveAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to BlogMarksAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to WinkAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to TechnoratiAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to Feed Me LinksAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to LinkaGoGoAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to BlueDotAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to Mister WongAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to TailRankAdd FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes to Yahoo Bookmarks

Comments

No comments found... be the first one to comment on this story :)

Post a Comment
Name:
   
E-Mail Address:
   
Website / Blog URL (optional):
   
Comments:
   
Security Code:
   
  
   By submitting these comments, you are agreeing to our Terms of Service
    
Latest News
Latest News World News Pakistan News Technology News Entertainment News Business News Sports News
bullet Senate HELP Committee To Hold Hearing Today On Nomination Of Daschle As New HHS Secretary
bullet PBS 'NewsHour With Jim Lehrer' Series Examines Health Care Challenges For Obama, Congress
bullet Proposed Colorado Hospital Fee Could Fund Expansion Of Health Coverage To 200,000 State Residents
bullet Perspective Discusses Health Care Cost Containment; Kaiser Family Foundation President, CEO Discusses Prospects For Health Reform
bullet MSM Involved With HIV/AIDS Organization In Senegal Sentenced To Eight Years In Jail
bullet Yemen's Low Education Levels, High Poverty Rates Increasing HIV/AIDS Risk, Experts Say
bullet Folic Acid Supplements Help To Prevent Certain Birth Defects For Which Hispanic Women Have Increased Risk
bullet Plan To Cover The Uninsured Through Medicare
bullet Flu Dampens Web Users Enthusiasm For Sex, UK
bullet City Patients Urged To Have Their Say, UK
bullet Terrence Higgins Trust Launches Let's Get Tested - A New Film Competition For 15-25 Year Olds, UK
bullet Before Mating Mosquitoes Create Harmonic Love Song, a Cornell Study Finds
bullet Whole Genome Study Reveals Clues To Solving The Mystery Behind Kawasaki Disease
bullet UCB And WILEX To Enter Into Strategic Alliance To Develop UCB's Preclinical Oncology Portfolio
bullet Steady Rates Of Obesity Not Good Enough - Australian Medical Association
bullet Discovery Of Gene That Increases Susceptibility To Crohn's Disease
bullet Alliance For Pediatric Quality Supports New ANSI-Approved Standard For Child Health Passed By HL7
bullet Research Sheds Light On How The Nerve Supply To The Cardiovascular System Is Established During Development
bullet Knee Replacement Boosts Mobility, Physical Ability In Patients
bullet Mechanism For Dental Pain Uncovered By OHSU School Of Dentistry
bullet U.S. To Fund HPV Vaccination Campaign In Micronesia Region
bullet President-Elect Obama Says Overhauling Entitlement Programs 'A Central Part' Of Administration Spending Control Efforts
bullet Nine FDA Scientists Ask Obama Transition Team To Implement Reforms At Agency
bullet House Democrats Plan To Vote On Stand-Alone SCHIP Reauthorization Bill
bullet Several Recent Editorials, Opinion Pieces Discuss Economic Stimulus Package
 
© 2007 Verge Systems